[1] Lazaridis KN, LaRusso NF. The Cholangiopathies. Mayo Clin Proc,2015,90:791-800.
[2] Netea MG, Joosten LA, Latz E, et al. Trained immunity: A program of innate immune memory in health and disease. Science,2016,352:aaf1098.
[3] Mulder WJM, Ochando J, Joosten LAB, et al. Therapeutic targeting of trained immunity. Nat Rev Drug Discov,2019,18:553-566.
[4] Netea MG, Domínguez-Andrés J, Barreiro LB, et al. Defining trained immunity and its role in health and disease. Nat Rev Immunol,2020,20:375-388.
[5] Keshavarzian A, Farhadi A, Forsyth CB, et al. Evidence that chronic alcohol exposure promotes intestinal oxidative stress, intestinal hyperpermeability and endotoxemia prior to development of alcoholic steatohepatitis in rats. J Hepatol,2009,50:538-547.
[6] Sabino J, Vieira-Silva S, Machiels K, et al. Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD. Gut,2016,65:1681-1689.
[7] Bajer L, Kverka M, Kostovcik M, et al. Distinct gut microbiota profiles in patients with primary sclerosing cholangitis and ulcerative colitis. World J Gastroenterol, 2017,23:4548-4558.
[8] Lv Z, Zhao D, Chang J, et al. Anti-bacterial and Anti-biofilm Evaluation of Thiazolopyrimidinone Derivatives Targeting the Histidine Kinase YycG Protein of Staphylococcus epidermidis. Front Microbiol,2017,8:549.
[9] Allegretti JR, Kassam Z, Carrellas M, et al. Fecal Microbiota Transplantation in Patients With Primary Sclerosing Cholangitis: A Pilot Clinical Trial. Am J Gastroenterol, 2019,114:1071-1079.
[10] Yan C, Koda S, Wu J, et al. Roles of Trained Immunity in the Pathogenesis of Cholangiopathies: A Therapeutic Target. Hepatology,2020,72:1838-1850.
[11] Isse K, Harada K, Zen Y, et al. Fractalkine and CX3CR1 are involved in the recruitment of intraepithelial lymphocytes of intrahepatic bile ducts. Hepatology,2005,41:506-516.
[12] Jo EK, Kim JK, Shin DM, et al. Molecular mechanisms regulating NLRP3 inflammasome activation. Cell Mol Immunol,2016,13:148-159.
[13] Ma WT, Gao F, Gu K, et al. The Role of Monocytes and Macrophages in Autoimmune Diseases: A Comprehensive Review. Front Immunol,2019,10:1140.
[14] Mao TK, Lian ZX, Selmi C, et al. Altered monocyte responses to defined TLR ligands in patients with primary biliary cirrhosis. Hepatology,2005,42:802-808.
[15] Atanasov G, Dietel C, Feldbrügge L, et al. Tumor necrosis and infiltrating macrophages predict survival after curative resection for cholangiocarcinoma. Oncoimmunology, 2017,6:e1331806.
[16] Vergadi E, Ieronymaki E, Lyroni K, et al. Akt Signaling Pathway in Macrophage Activation and M1/M2 Polarization. J Immunol,2017,198:1006-1014.
[17] Soraya H, Rameshrad M, Mokarizadeh A, et al. Metformin attenuates myocardial remodeling and neutrophil recruitment after myocardial infarction in rat. Bioimpacts, 2015,5:3-8.
[18] Lleo A, Liao J, Invernizzi P, et al. Immunoglobulin M levels inversely correlate with CD40 ligand promoter methylation in patients with primary biliary cirrhosis. Hepatology, 2012,55:153-160.
[19] Cheung AC, LaRusso NF, Gores GJ, et al. Epigenetics in the Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. Semin Liver Dis,2017,37:159-174.
[20] Baghdasaryan A, Claudel T, Kosters A, et al. Curcumin improves sclerosing cholangitis in Mdr2-/- mice by inhibition of cholangiocyte inflammatory response and portal myofibroblast proliferation. Gut,2010,59:521-530. |
